Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

This publication has 71 references indexed in Scilit:

• Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5′-Upstream Regulatory Region
  Biochemical and Biophysical Research Communications, 1999
• Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
  The Lancet, 1999
• Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole
  British Journal of Clinical Pharmacology, 1998
• Laying the foundations for personalized medicines
  Nature Biotechnology, 1997
• Genetic polymorphism of CYP2D6 and lung cancer risk in African- Americans and Caucasians in Los Angeles County
  Carcinogenesis: Integrative Cancer Research, 1997
• Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions
  Clinical Pharmacokinetics, 1997
• A novel mutant variant of the CYP2D6 gene (CYP2D617) common in a black African population: association with diminished debrisoquine hydroxylase activity
  British Journal of Clinical Pharmacology, 1996
• Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population
  Pharmacogenetics, 1996
• The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine
  British Journal of Clinical Pharmacology, 1996
• Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects
  Pharmacogenetics, 1992